Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of MEDI8897 to prevent medically attended RSV lower respiratory tract infection in healthy preterm infants has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• MEDI8897

Snippet

Sponsor: MedImmune LLC | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: COMPLETED | Results posted: 2019-10-14